The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy
| Autor: | Loretta J. Nastoupil, Rajni Sinha, Christopher R. Flowers |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty Chronic lymphocytic leukemia medicine.medical_treatment Purine analogue Antineoplastic Agents Targeted therapy Chemoimmunotherapy hemic and lymphatic diseases Internal medicine medicine Humans Pharmacology (medical) Molecular Targeted Therapy Chemotherapy business.industry Standard treatment Antibodies Monoclonal medicine.disease Leukemia Lymphocytic Chronic B-Cell Leukemia Immunology Rituximab business medicine.drug |
| Zdroj: | Expert Review of Anticancer Therapy. 13:1089-1108 |
| ISSN: | 1744-8328 1473-7140 |
| Popis: | For many years, alkylating agents were the standard treatment for chronic lymphocytic leukemia (CLL). The advent of purine analogs improved response rates, but not overall survival, and although the monoclonal antibody rituximab is generally active against B-cell malignancies, it has demonstrated limited benefits as monotherapy for the treatment of CLL. However, specific combinations of chemotherapy, antibodies and targeted therapies have demonstrated additive or synergistic activity in CLL cells and deliver substantial clinical benefits. A greater understanding of the actions of chemotherapies and targeted agents on cellular pathways will advance the development of rationally designed combinations corresponding to individual patients' disease profiles. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|